Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells-Reference-Cited by-同舟云学术

Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells

Published:2011-01-10 Issue:2 Volume:53 Page:649-660
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Petrasek Jan,Dolganiuc Angela,Csak Timea,Nath Bharath,Hritz Istvan,Kodys Karen,Catalano Donna,Kurt-Jones Evelyn,Mandrekar Pranoti,Szabo Gyongyi

Publisher

Wiley

Subject

Hepatology

Reference36 articles.

1. Burden of liver disease in the United States: summary of a workshop;Kim;HEPATOLOGY,2002

2. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?;Bode;Alcohol Clin Exp Res,2005

3. Role of Kupffer cells in alcoholic hepatitis;Nanji;Alcohol,2002

4. Endotoxin and Kupffer cell activation in alcoholic liver disease;Wheeler;Alcohol Res Health,2003

5. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice;Yin;Gastroenterology,1999

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging concepts in alcohol, infection & immunity: A summary of the 2023 alcohol and immunology research interest group (AIRIG) meeting;Alcohol;2024-08

2. The Role of Interferon Regulatory Factors in Liver Diseases;International Journal of Molecular Sciences;2024-06-22

3. TRIF-dependent signaling and its role in liver diseases;Frontiers in Cell and Developmental Biology;2024-04-17

4. Transcriptotype-Driven Discovery of Apigenin as a Therapy against Cholestatic Liver Fibrosis: Through Inhibition of PANoptosis and Following Type-I Interferon Responses;Antioxidants;2024-02-20

5. Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis;Pharmaceuticals;2024-02-19